MyoKardia Readies First-Ever Hypertrophic Cardiomyopathy Drug For US Filing

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The Phase III EXPLORER-HCM trial evaluating mavacamten in obstructive hypertrophic cardiomyopathy (oHCM) succeeded on all primary and secondary endpoints.

heart surround with pharmaceutical medicine pills and tablets, a flask and a pill box on blue background, heart health and treatment. top view. health concept
MyoKardia's once-daily pill bested placebo on all efficacy measures • Source: Shutterstock

MyoKardia Inc. plans to file mavacamten with the US Food and Drug Administration in the first quarter of 2021 based on results from the Phase III EXPLORER-HCM clinical trial in obstructive hypertrophic cardiomyopathy (oHCM). The company reported on 11 May that patients treated with the oral drug were less likely to experience shortness of breath than those who received placebo in the pivotal trial, and half of the patients treated with mavacamten were deemed asymptomatic by the end of the study.

The EXPLORER-HCM results show that the allosteric modulator of cardiac myosin improved patients’ heart function and symptoms while proving at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D